Biocept and Providence Saint John's Health Center Collaborate to Evaluate Cerebrospinal Fluid

Thursday, Feb 28, 2019

Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will collaborate with Providence St. Joseph Health, Southern California, and its wholly owned affiliates Providence Saint John's Health Center and the John Wayne Cancer Institute, to conduct a study to validate the use of cerebrospinal fluid (CSF) as a specimen type with Biocept's Target Selector™ liquid biopsy platform.

In patients diagnosed with certain cancers, leptomeningeal metastases (LM) can occur when tumor cells gain access to CSF pathways and regrow in distant sites within the spinal cord and brain. Biocept's liquid biopsy platform will be used to test the CSF of patients diagnosed with certain types of cancer, such as breast, lung and melanoma, as well as other malignancies to determine if LM has occurred. The results from Biocept's liquid biopsy testing will be compared to standard methods for confirming the diagnosis of LM.

"We look forward to using Biocept's Target Selector™ technology to evaluate oncologic biomarkers in the CSF of patients with cancer, with the potential to validate a rapid and accurate solution for confirming LM," stated Santosh Kesari, MD, PhD, Chairman and Professor, Department of Translational Neurosciences and Neurotherapeutics, Director of Neuro-oncology at the Pacific Neuroscience Institute and John Wayne Cancer Institute. "This study is aimed at addressing a major need in the treatment of metastatic disease, given the devastating nature of LM involvement in many cancer types."

"We are very pleased to collaborate with Dr. Kesari and Providence St. Joseph Health in this study designed to further validate the clinical utility of our Target Selector™ platform using the CSF of patients with cancer," said Michael W. Nall, President and CEO of Biocept. "Among the significant advantages of our liquid biopsy technology is its versatility, which enables its application in a variety of clinical situations and for use with multiple types of biofluids. Results of this study could open new market opportunities for Biocept."



Other News